A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT05645107 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

386

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypogammaglobulinemia
Bacterial Infections
B-cell Chronic Lymphocytic Leukemia
Multiple Myleoma
Non-Hodgkin Lymphoma

Interventions

DRUG: Xembify
DRUG: Placebo

Sponsor

Grifols Therapeutics LLC